Skip to main content
main-content

ACR Convergence 2020 highlights

5 – 9 November


This information is brought to you by medwireNews and is not sponsored by, nor a part of, the American College of Rheumatology.


ACR Convergence 2020 news

‘The Great Debate’: JAK inhibitors vs biologics following methotrexate failure in RA

iStock-1129164716

“The Great Debate” of the ACR Convergence 2020 virtual meeting addressed the question of whether JAK inhibitors should be given before biologics following an inadequate response to methotrexate in patients with rheumatoid arthritis.

ACR Convergence 2020 news

Secukinumab reduces spinal pain in patients with axSpA

Spine pain

Secukinumab significantly reduces spinal pain in patients with axial spondyloarthritis, with benefits seen after just 8 weeks, findings from the SKIPPAIN trial show.

ACR Convergence 2020 news

BIIB059 improves total active joint count in systemic lupus erythematosus

3x1_AdobeStock_248701149

BIIB059, a monoclonal antibody that binds blood dendritic cell antigen 2 and inhibits interferon 1, improves total active joint count at 24 weeks in patients with systemic lupus erythematosus, findings from the LILAC trial show.

ACR Convergence 2020 news

ULTIMATE trial: Secukinumab reduces synovitis in patients with PsA

Synovitis pain

Phase 3 trial results suggest that secukinumab treatment reduces synovitis among biologic-naïve patients with psoriatic arthritis and an inadequate response to conventional DMARDs.

ACR Convergence 2020 news

Better maintenance of remission with etanercept vs methotrexate monotherapy in the SEAM-RA trial

3x1_AdobeStock_304058348

Among rheumatoid arthritis patients in sustained remission on combination therapy, withdrawal of methotrexate is associated with better outcomes than withdrawal of etanercept, indicate findings from the SEAM-RA trial.

ACR Convergence 2020 news

Secukinumab may reduce the burden of Achilles tendon enthesitis in patients with spondyloarthritis

Achilles pain

The IL-17A inhibitor secukinumab may improve pain and disease activity among patients with psoriatic arthritis or axial spondyloarthritis and imaging-confirmed enthesitis at the Achilles tendon, suggest findings from the ACHILLES trial.

Expert interviews

Latest research news

11-11-2020 | ACR 2020 | Conference coverage | News

​​​​​​​BIIB059 shows potential for cutaneous lupus erythematosus

Findings from the second part of the LILAC trial suggest that BIIB059, a monoclonal antibody targeting blood dendritic cell antigen 2, improves skin outcomes for patients with active cutaneous lupus erythematosus.

11-11-2020 | ACR 2020 | Conference coverage | News

‘The Great Debate’: JAK inhibitors vs biologics following methotrexate failure in RA

“The Great Debate” of the ACR Convergence 2020 virtual meeting addressed the question of whether JAK inhibitors should be given before biologics following an inadequate response to methotrexate in patients with rheumatoid arthritis.

11-11-2020 | ACR 2020 | Conference coverage | News

​​​​​​​Early findings encouraging for deucravacitinib in psoriatic arthritis

Deucravacitinib, a novel selective tyrosine kinase 2 inhibitor, may be a promising treatment option for patients with psoriatic arthritis, suggest phase 2 data presented in a poster at the ACR Convergence 2020 virtual meeting.

09-11-2020 | ACR 2020 | Conference coverage | News

T2T strategy shows benefits for patients with axSpA


Medicine Matters conference coverage is brought to you in partnership with medwireNews


Image Credits